Novalung
| Novalung GmbH | |
|---|---|
| legal form | GmbH |
| founding | 2003 |
| Seat | Heilbronn , Germany |
| management | Jürgen Bohm |
| Number of employees | 280 (2019) |
| Branch | Medical technology |
| Website | www.xenios-ag.com/novalung |
The Nova Lung GmbH is a German medical technology company based in Heilbronn and the first company in the world to one without a pump operated gas exchanger for extrapulmonary carbon dioxide using removal.
Novalung was founded in 2003 in Hechingen . In 2004 the subsidiary Novalung Inc. was founded in Ann Arbor , USA. There is cooperation with a research group from MC3. In 2008 the company headquarters was relocated to Talheim , 2010 to Heilbronn. Production, which has been in Oberstenfeld since the end of 2009 , was also relocated to Heilbronn in 2013.
Novalung's products, e.g. B. the iLA membrane ventilator and NovaPort cannulas represent an alternative to the treatment of lung failure . An artificial lung , which is connected to the patient's bloodstream, carries out the gas exchange that the damaged lung can no longer perform. The concentrations of the blood gases are returned to a physiological range. Together with leading international doctors, new therapies to replace invasive ventilation are being developed. Clinical studies and case studies of individual patients have shown that the iLA membrane ventilator can be used to help some patients with lung failure in over 4000 clinical deployments.
The use of mechanical ventilation can be avoided by using an iLA membrane fan. In the first patients, the iLA membrane ventilator was used to bridge the waiting time before a lung transplant .
The clinical publications are compiled and commented on in the Compendium of Evidence for the iLA membrane ventilator.
history
Novalung GmbH started its business activities at the Hechingen location in 2003. The iLA membrane fan is CE marked . A research cooperation with HIMOX was concluded. A research project was carried out on a percutaneously insertable lung that lies in the vena cava without resistance. A development and technology cooperation was started with a leading research group on artificial lungs in the USA. Novalung founded Novalung Inc. in Ann Arbor , USA, in 2005 for cooperation in the North American market. In 2005 Novalung moved into a class 100,000 clean room production facility with an area of 300 m². The Vision-α high frequency ventilator was launched in 2007. The headquarters of Novalung GmbH was relocated from Hechingen to Talheim , Heilbronn district . The VentProtect, a filter heater for use with the high-frequency ventilator Vision α, was introduced. Production was relocated to Oberstenfeld in 2009 and relocated to the headquarters in Heilbronn in 2013 .
In 2011, Novalung GmbH took over Aachen-based Medos Medizintechnik AG in order to expand Medos' blood pump expertise and blood pump technology for use in lung therapies. In 2013 Novalung and Medos merged with the establishment of a holding company, Xenios AG . Xenios AG has been part of Fresenius Medical Care since the end of 2016 . At the end of August 2019, Novalung GmbH was completely integrated into Xenios AG.
Web links
Individual evidence
- ↑ "Innovations in technology - Novalung iLA: challenges for the field of critical care nursing"
- ↑ “Artificial Lung Researchers Encouraged by Initial Data” .
- ↑ Chris Löwer: The artificial lung has proven itself in practice . In: Handelsblatt of September 5, 2006
- ^ "Artificial lung kept teen alive until transplant" .
- ↑ "Tiny artificial lung breathes life into Ontario mother"
- ↑ "Compendium of Evidence" ( Memento of the original from January 8, 2014 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. (pdf)
